



(11) **EP 1 395 605 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 2 (W2 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 72**

(51) Int Cl.:  
**A61K 39/395** <sup>(2006.01)</sup> **C07K 16/00** <sup>(2006.01)</sup>  
**C12N 15/13** <sup>(2006.01)</sup> **C12N 15/62** <sup>(2006.01)</sup>  
**C07K 19/00** <sup>(2006.01)</sup>

(48) Corrigendum issued on:  
**17.12.2014 Bulletin 2014/51**

(86) International application number:  
**PCT/US2002/007365**

(45) Date of publication and mention  
of the grant of the patent:  
**14.05.2014 Bulletin 2014/20**

(87) International publication number:  
**WO 2002/072608 (19.09.2002 Gazette 2002/38)**

(21) Application number: **02719196.4**

(22) Date of filing: **11.03.2002**

(54) **POLYMERIC IMMUNOGLOBULIN FUSION PROTEINS THAT TARGET LOW-AFFINITY FCGAMMA RECEPTORS**

POLYMERE IMMUNOGLOBULIN-FUSIONSPROTEINE, DIE AUF FC-GAMMA-REZEPTOREN MIT GERINGER AFFINITÄT ZIELEN

PROTEINES HYBRIDES D'IMMUNOGLOBULINES POLYMERIQUES CIBLANT DES RECEPTEURS FCGAMMA A FAIBLE AFFINITE

(84) Designated Contracting States:  
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**

(30) Priority: **09.03.2001 US 274392 P**

(43) Date of publication of application:  
**10.03.2004 Bulletin 2004/11**

(73) Proprietor: **Iterative Therapeutics, Inc.**  
**Chicago, IL 60612 (US)**

(72) Inventors:  
• **ARNASON, Barry G.**  
**Chicago, IL 60615 (US)**  
• **JENSEN, Mark A.**  
**Chicago, IL 60657 (US)**  
• **WHITE, David M.**  
**Chicago, IL 60615 (US)**

(74) Representative: **Barton, Matthew Thomas**  
**Forresters**  
**Skygarden**  
**Erika-Mann-Strasse 11**  
**80636 München (DE)**

(56) References cited:  
**WO-A-00/42072 WO-A1-92/10591**  
**WO-A1-99/58572**

- **WHITE DAVID M ET AL: "Design and expression of polymeric immunoglobulin fusion proteins: A strategy for targeting low-affinity Fcgamma receptors" PROTEIN EXPRESSION AND PURIFICATION, vol. 21, no. 3, April 2001 (2001-04), pages 446-455, XP002282485 ISSN: 1046-5928**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 395 605 B8**

- SHIELDS R L ET AL: "High resolution mapping of the binding site on human IgG1 for Fcγ<sub>1</sub>R, Fcγ<sub>2</sub>R, Fcγ<sub>3</sub>R, and Fcγ<sub>4</sub>R and design of IgG1 variants with improved binding to the Fcγ<sub>2</sub>R" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 9, 2 March 2001 (2001-03-02), pages 6591-6604, XP002271092 ISSN: 0021-9258
- MORGAN A ET AL: "THE N-TERMINAL END OF THE CH2 DOMAIN OF CHIMERIC HUMAN IGG1 ANTI-HLA-DR IS NECESSARY FOR C1Q, FCGAMMARI AND FCGAMMARIII BINDING" IMMUNOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, GB, vol. 86, no. 2, October 1995 (1995-10), pages 319-324, XP001106372 ISSN: 0019-2805
- COLOMA M J ET AL: "DESIGN AND PRODUCTION OF NOVEL TETRAVALENT BISPECIFIC ANTIBODIES" NATURE BIOTECHNOLOGY, NATURE PUBLISHING, US, vol. 15, no. 2, 1 February 1997 (1997-02-01), pages 159-163, XP000647731 ISSN: 1087-0156